Emerging treatment for advanced lung cancer with EGFR mutation

Cengiz Inal, Emrullah Yilmaz, Bilal Piperdi, Roman Perez-Soler, Haiying Cheng

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Lung cancer is the leading cause of cancer-related death worldwide. It is usually diagnosed at advanced stage for which platinum-based chemotherapy had been the standard approach, although with limited clinical benefits. Discovery of oncogenic EGFR mutations in lung cancer have shifted the treatment paradigm with molecularly targeted therapies.Areas covered: EGFR tyrosine kinase inhibitors (TKIs) have become the first-line choice in patients with advanced NSCLC harboring EGFR activating mutations. However, resistance to targeted therapy develops inevitably during the course of treatment. Multiple mechanisms of acquired resistance have been discovered, most commonly the secondary mutation of T790M in exon 20. The second- and third-generation EGFR TKIs are holding promise to overcome T790M-associated acquired resistance and currently being tested in clinical trials. In this article, we focus on the emerging approaches to overcome the different mechanisms of resistance to targeted therapies in patients with EGFR-mutant advanced NSCLC.Expert opinion: It is essential to uncover the complex mechanisms underlying the progression of lung cancer after upfront EGFR TKIs. Next generation, in particular, the third generations of EGFR TKIs have been developed against acquired T790M mutation with promising clinical activity and better toxicity profile. Combination of targeted therapies has also been explored. Further studies are needed to detect the real-time changes of the resistance mechanisms and to develop new therapeutic strategies for lung cancer patients with EGFR mutations.

Original languageEnglish (US)
Pages (from-to)597-612
Number of pages16
JournalExpert Opinion on Emerging Drugs
Volume20
Issue number4
DOIs
StatePublished - Oct 2 2015

Fingerprint

Lung Neoplasms
Mutation
Protein-Tyrosine Kinases
Therapeutics
Expert Testimony
Platinum
Exons
Clinical Trials
Drug Therapy
Neoplasms

Keywords

  • combination of targeted therapies
  • EGFR
  • NSCLC
  • resistance mechanisms
  • T790M mutation
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging treatment for advanced lung cancer with EGFR mutation. / Inal, Cengiz; Yilmaz, Emrullah; Piperdi, Bilal; Perez-Soler, Roman; Cheng, Haiying.

In: Expert Opinion on Emerging Drugs, Vol. 20, No. 4, 02.10.2015, p. 597-612.

Research output: Contribution to journalArticle

@article{eaf2ef7c83504f53a595457cdadd2fcb,
title = "Emerging treatment for advanced lung cancer with EGFR mutation",
abstract = "Introduction: Lung cancer is the leading cause of cancer-related death worldwide. It is usually diagnosed at advanced stage for which platinum-based chemotherapy had been the standard approach, although with limited clinical benefits. Discovery of oncogenic EGFR mutations in lung cancer have shifted the treatment paradigm with molecularly targeted therapies.Areas covered: EGFR tyrosine kinase inhibitors (TKIs) have become the first-line choice in patients with advanced NSCLC harboring EGFR activating mutations. However, resistance to targeted therapy develops inevitably during the course of treatment. Multiple mechanisms of acquired resistance have been discovered, most commonly the secondary mutation of T790M in exon 20. The second- and third-generation EGFR TKIs are holding promise to overcome T790M-associated acquired resistance and currently being tested in clinical trials. In this article, we focus on the emerging approaches to overcome the different mechanisms of resistance to targeted therapies in patients with EGFR-mutant advanced NSCLC.Expert opinion: It is essential to uncover the complex mechanisms underlying the progression of lung cancer after upfront EGFR TKIs. Next generation, in particular, the third generations of EGFR TKIs have been developed against acquired T790M mutation with promising clinical activity and better toxicity profile. Combination of targeted therapies has also been explored. Further studies are needed to detect the real-time changes of the resistance mechanisms and to develop new therapeutic strategies for lung cancer patients with EGFR mutations.",
keywords = "combination of targeted therapies, EGFR, NSCLC, resistance mechanisms, T790M mutation, tyrosine kinase inhibitors",
author = "Cengiz Inal and Emrullah Yilmaz and Bilal Piperdi and Roman Perez-Soler and Haiying Cheng",
year = "2015",
month = "10",
day = "2",
doi = "10.1517/14728214.2015.1058778",
language = "English (US)",
volume = "20",
pages = "597--612",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging treatment for advanced lung cancer with EGFR mutation

AU - Inal, Cengiz

AU - Yilmaz, Emrullah

AU - Piperdi, Bilal

AU - Perez-Soler, Roman

AU - Cheng, Haiying

PY - 2015/10/2

Y1 - 2015/10/2

N2 - Introduction: Lung cancer is the leading cause of cancer-related death worldwide. It is usually diagnosed at advanced stage for which platinum-based chemotherapy had been the standard approach, although with limited clinical benefits. Discovery of oncogenic EGFR mutations in lung cancer have shifted the treatment paradigm with molecularly targeted therapies.Areas covered: EGFR tyrosine kinase inhibitors (TKIs) have become the first-line choice in patients with advanced NSCLC harboring EGFR activating mutations. However, resistance to targeted therapy develops inevitably during the course of treatment. Multiple mechanisms of acquired resistance have been discovered, most commonly the secondary mutation of T790M in exon 20. The second- and third-generation EGFR TKIs are holding promise to overcome T790M-associated acquired resistance and currently being tested in clinical trials. In this article, we focus on the emerging approaches to overcome the different mechanisms of resistance to targeted therapies in patients with EGFR-mutant advanced NSCLC.Expert opinion: It is essential to uncover the complex mechanisms underlying the progression of lung cancer after upfront EGFR TKIs. Next generation, in particular, the third generations of EGFR TKIs have been developed against acquired T790M mutation with promising clinical activity and better toxicity profile. Combination of targeted therapies has also been explored. Further studies are needed to detect the real-time changes of the resistance mechanisms and to develop new therapeutic strategies for lung cancer patients with EGFR mutations.

AB - Introduction: Lung cancer is the leading cause of cancer-related death worldwide. It is usually diagnosed at advanced stage for which platinum-based chemotherapy had been the standard approach, although with limited clinical benefits. Discovery of oncogenic EGFR mutations in lung cancer have shifted the treatment paradigm with molecularly targeted therapies.Areas covered: EGFR tyrosine kinase inhibitors (TKIs) have become the first-line choice in patients with advanced NSCLC harboring EGFR activating mutations. However, resistance to targeted therapy develops inevitably during the course of treatment. Multiple mechanisms of acquired resistance have been discovered, most commonly the secondary mutation of T790M in exon 20. The second- and third-generation EGFR TKIs are holding promise to overcome T790M-associated acquired resistance and currently being tested in clinical trials. In this article, we focus on the emerging approaches to overcome the different mechanisms of resistance to targeted therapies in patients with EGFR-mutant advanced NSCLC.Expert opinion: It is essential to uncover the complex mechanisms underlying the progression of lung cancer after upfront EGFR TKIs. Next generation, in particular, the third generations of EGFR TKIs have been developed against acquired T790M mutation with promising clinical activity and better toxicity profile. Combination of targeted therapies has also been explored. Further studies are needed to detect the real-time changes of the resistance mechanisms and to develop new therapeutic strategies for lung cancer patients with EGFR mutations.

KW - combination of targeted therapies

KW - EGFR

KW - NSCLC

KW - resistance mechanisms

KW - T790M mutation

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84950286284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950286284&partnerID=8YFLogxK

U2 - 10.1517/14728214.2015.1058778

DO - 10.1517/14728214.2015.1058778

M3 - Article

VL - 20

SP - 597

EP - 612

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -